Our Focus

  • 1. Cost-Efficient Bio-Tech Accelerator

    Utah Health Entrepreneurs and the Macroeconomic Bio-Tech Entrepreneurship Accelerator are uniquely focused on cost education and capital efficient outcomes

  • 2. Investment Platform for Preclinical Costs

    There are no other investment platforms that educate and evaluate the costs of preclinical animal testing in the startup regulatory pathway

  • 3. AI & Biotech Cost-Efficiency Accelerator

    There are no other accelerators that cater exclusively to cost efficiency technology ranging from artificial intelligence (AI) and supercomputing to 3D bio-printing and synthetic engineering

  • 4. Low Success Rate for Phase I Drug Trials

    Chances of success for a drug compound entering Phase I trials have not increased in the past two decades: it's still slightly under 10%

  • 5. High Failure Rate Unmatched in Other Industries

    No other major business type operates under such a high failure rate

  • 6. Massive Capital Losses in US Startups & Scaleups

    Using a sample of 2245 US startups & scaleups with an average capital first investment of $5,000,000 shows a 90% loss of  $11,225,000,000 in capital investments

  • 7. Surviving 10% Must Justify Annual Capital Losses

    The 10% that “make it” in Phase I have to  justify that capital asset loss each and every year!

Deal Flow Objectives

  • 1

    Provide educational activities that focus on costs of innovation

  • 2

    Find and fund innovative approaches to drug innovation that improve success rates at lower costs

  • 3

    Provide deal flow that reduce capital allocation risk

  • 4

    Establish the Macroeconomic Bio-Tech Entrepreneurship Accelerator as a profitable model for national innovative biotech development